

Mark C Genovese

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/140798/publications.pdf>

Version: 2024-02-01

167
papers

19,019
citations

22153

59
h-index

11607

135
g-index

169
all docs

169
docs citations

169
times ranked

13019
citing authors

#	ARTICLE	IF	CITATIONS
1	A Comparison of Etanercept and Methotrexate in Patients with Early Rheumatoid Arthritis. <i>New England Journal of Medicine</i> , 2000, 343, 1586-1593.	27.0	1,776
2	Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. <i>Arthritis and Rheumatism</i> , 2006, 54, 2793-2806.	6.7	1,462
3	Abatacept for Rheumatoid Arthritis Refractory to Tumor Necrosis Factor \pm Inhibition. <i>New England Journal of Medicine</i> , 2005, 353, 1114-1123.	27.0	1,157
4	Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: The tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study. <i>Arthritis and Rheumatism</i> , 2008, 58, 2968-2980.	6.7	752
5	Etanercept versus methotrexate in patients with early rheumatoid arthritis: Two-year radiographic and clinical outcomes. <i>Arthritis and Rheumatism</i> , 2002, 46, 1443-1450.	6.7	664
6	Lymphocyte Cc Chemokine Receptor 9 and Epithelial Thymus-Expressed Chemokine (Teck) Expression Distinguish the Small Intestinal Immune Compartment. <i>Journal of Experimental Medicine</i> , 2000, 192, 761-768.	8.5	607
7	Baricitinib in Patients with Refractory Rheumatoid Arthritis. <i>New England Journal of Medicine</i> , 2016, 374, 1243-1252.	27.0	499
8	Combination therapy with etanercept and anakinra in the treatment of patients with rheumatoid arthritis who have been treated unsuccessfully with methotrexate. <i>Arthritis and Rheumatism</i> , 2004, 50, 1412-1419.	6.7	478
9	2021 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. <i>Arthritis Care and Research</i> , 2021, 73, 924-939.	3.4	466
10	Tofacitinib in Combination With Nonbiologic Disease-Modifying Antirheumatic Drugs in Patients With Active Rheumatoid Arthritis. <i>Annals of Internal Medicine</i> , 2013, 159, 253.	3.9	381
11	An Oral Spleen Tyrosine Kinase (Syk) Inhibitor for Rheumatoid Arthritis. <i>New England Journal of Medicine</i> , 2010, 363, 1303-1312.	27.0	369
12	Brodalumab, an Anti-IL17RA Monoclonal Antibody, in Psoriatic Arthritis. <i>New England Journal of Medicine</i> , 2014, 370, 2295-2306.	27.0	350
13	Phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) or adalimumab monotherapy versus placebo in patients with active rheumatoid arthritis with an inadequate response to disease-modifying antirheumatic drugs. <i>Arthritis and Rheumatism</i> , 2012, 64, 617-629.	6.7	339
14	2021 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. <i>Arthritis and Rheumatology</i> , 2021, 73, 1108-1123.	5.6	339
15	Ixekizumab for the treatment of patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors: results from the 24-week randomised, double-blind, placebo-controlled period of the SPIRIT-P2 phase 3 trial. <i>Lancet, The</i> , 2017, 389, 2317-2327.	13.7	316
16	Safety and efficacy of upadacitinib in patients with active rheumatoid arthritis refractory to biologic disease-modifying anti-rheumatic drugs (SELECT-BEYOND): a double-blind, randomised controlled phase 3 trial. <i>Lancet, The</i> , 2018, 391, 2513-2524.	13.7	316
17	Demyelinating and neurologic events reported in association with tumor necrosis factor ? antagonism: By what mechanisms could tumor necrosis factor ? antagonists improve rheumatoid arthritis but exacerbate multiple sclerosis?. <i>Arthritis and Rheumatism</i> , 2001, 44, 1977-1983.	6.7	296
18	Upadacitinib Versus Placebo or Adalimumab in Patients With Rheumatoid Arthritis and an Inadequate Response to Methotrexate: Results of a Phase III, Double-Blind, Randomized Controlled Trial. <i>Arthritis and Rheumatology</i> , 2019, 71, 1788-1800.	5.6	284

#	ARTICLE	IF	CITATIONS
19	Abatacept in the treatment of patients with psoriatic arthritis: Results of a six-month, multicenter, randomized, double-blind, placebo-controlled, phase II trial. <i>Arthritis and Rheumatism</i> , 2011, 63, 939-948.	6.7	264
20	Efficacy and safety of secukinumab in patients with rheumatoid arthritis: a phase II, dose-finding, double-blind, randomised, placebo controlled study. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 863-869.	0.9	263
21	Antigen microarray profiling of autoantibodies in rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 2005, 52, 2645-2655.	6.7	256
22	Safety and efficacy of baricitinib at 24-weeks in patients with rheumatoid arthritis who have had an inadequate response to methotrexate. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 333-340.	0.9	232
23	Sarilumab Plus Methotrexate in Patients With Active Rheumatoid Arthritis and Inadequate Response to Methotrexate: Results of a Phase III Study. <i>Arthritis and Rheumatology</i> , 2015, 67, 1424-1437.	5.6	213
24	Effect of Filgotinib vs Placebo on Clinical Response in Patients With Moderate to Severe Rheumatoid Arthritis Refractory to Disease-Modifying Antirheumatic Drug Therapy. <i>JAMA - Journal of the American Medical Association</i> , 2019, 322, 315.	7.4	210
25	Safety Profile of Baricitinib in Patients with Active Rheumatoid Arthritis with over 2 Years Median Time in Treatment. <i>Journal of Rheumatology</i> , 2019, 46, 7-18.	2.0	207
26	Selective tyrosine kinase inhibition by imatinib mesylate for the treatment of autoimmune arthritis. <i>Journal of Clinical Investigation</i> , 2006, 116, 2633-2642.	8.2	194
27	Ocrelizumab, a humanized anti-CD20 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: A phase I/II randomized, blinded, placebo-controlled, dose-ranging study. <i>Arthritis and Rheumatism</i> , 2008, 58, 2652-2661.	6.7	193
28	An oral Syk kinase inhibitor in the treatment of rheumatoid arthritis: A three-month randomized, placebo-controlled, phase II study in patients with active rheumatoid arthritis that did not respond to biologic agents. <i>Arthritis and Rheumatism</i> , 2011, 63, 337-345.	6.7	190
29	A Phase II Randomized Study of Subcutaneous Ixekizumab, an Anti-Interleukin-17 Monoclonal Antibody, in Rheumatoid Arthritis Patients Who Were Naive to Biologic Agents or Had an Inadequate Response to Tumor Necrosis Factor Inhibitors. <i>Arthritis and Rheumatology</i> , 2014, 66, 1693-1704.	5.6	188
30	Inhibition of p38: Has the fat lady sung?. <i>Arthritis and Rheumatism</i> , 2009, 60, 317-320.	6.7	182
31	Sarilumab, a fully human monoclonal antibody against IL-6 in patients with rheumatoid arthritis and an inadequate response to methotrexate: efficacy and safety results from the randomised SARIL-RA-MOBILITY Part A trial. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 1626-1634.	0.9	173
32	Efficacy and Safety of ABT494, a Selective JAK1 Inhibitor, in a Phase IIb Study in Patients With Rheumatoid Arthritis and an Inadequate Response to Methotrexate. <i>Arthritis and Rheumatology</i> , 2016, 68, 2857-2866.	5.6	172
33	IL-17 receptor and its functional significance in psoriatic arthritis. <i>Molecular and Cellular Biochemistry</i> , 2012, 359, 419-429.	3.1	171
34	Efficacy and safety of the biosimilar ABP 501 compared with adalimumab in patients with moderate to severe rheumatoid arthritis: a randomised, double-blind, phase III equivalence study. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 1679-1687.	0.9	138
35	Golimumab in patients with active rheumatoid arthritis despite methotrexate therapy: 52-week results of the GO-FORWARD study. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 1129-1135.	0.9	135
36	Safety and efficacy of adalimumab in treatment of patients with psoriatic arthritis who had failed disease modifying antirheumatic drug therapy. <i>Journal of Rheumatology</i> , 2007, 34, 1040-50.	2.0	135

#	ARTICLE	IF	CITATIONS
37	Efficacy and safety of olokizumab in patients with rheumatoid arthritis with an inadequate response to TNF inhibitor therapy: outcomes of a randomised Phase IIb study. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 1607-1615.	0.9	125
38	Filgotinib versus placebo or adalimumab in patients with rheumatoid arthritis and inadequate response to methotrexate: a phase III randomised clinical trial. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 848-858.	0.9	123
39	Continued inhibition of structural damage over 2 years in patients with rheumatoid arthritis treated with rituximab in combination with methotrexate. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 1158-1161.	0.9	115
40	Safety and effectiveness of upadacitinib or adalimumab plus methotrexate in patients with rheumatoid arthritis over 48 weeks with switch to alternate therapy in patients with insufficient response. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 1454-1462.	0.9	115
41	VX509 (Decernotinib), an Oral Selective JAK3 Inhibitor, in Combination With Methotrexate in Patients With Rheumatoid Arthritis. <i>Arthritis and Rheumatology</i> , 2016, 68, 46-55.	5.6	110
42	A 24-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study of the Efficacy of Oral SCIO-469, a p38 Mitogen-activated Protein Kinase Inhibitor, in Patients with Active Rheumatoid Arthritis. <i>Journal of Rheumatology</i> , 2011, 38, 846-854.	2.0	108
43	Longterm Safety and Efficacy of Tocilizumab in Patients with Rheumatoid Arthritis: A Cumulative Analysis of Up to 4.6 Years of Exposure. <i>Journal of Rheumatology</i> , 2013, 40, 768-780.	2.0	108
44	Gene expression changes reflect clinical response in a placebo-controlled randomized trial of abatacept in patients with diffuse cutaneous systemic sclerosis. <i>Arthritis Research and Therapy</i> , 2015, 17, 159.	3.5	104
45	Effects of Fostamatinib, an Oral Spleen Tyrosine Kinase Inhibitor, in Rheumatoid Arthritis Patients With an Inadequate Response to Methotrexate: Results From a Phase III, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study. <i>Arthritis and Rheumatology</i> , 2014, 66, 3255-3264.	5.6	96
46	Adalimumab long-term safety: infections, vaccination response and pregnancy outcomes in patients with rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 414-417.	0.9	94
47	Less Radiographic Progression with Adalimumab Plus Methotrexate Versus Methotrexate Monotherapy Across the Spectrum of Clinical Response in Early Rheumatoid Arthritis. <i>Journal of Rheumatology</i> , 2009, 36, 1429-1441.	2.0	89
48	Longterm safety, efficacy, and radiographic outcome with etanercept treatment in patients with early rheumatoid arthritis. <i>Journal of Rheumatology</i> , 2005, 32, 1232-42.	2.0	89
49	One-year Efficacy and Safety Results of Secukinumab in Patients With Rheumatoid Arthritis: Phase II, Dose-finding, Double-blind, Randomized, Placebo-controlled Study. <i>Journal of Rheumatology</i> , 2014, 41, 414-421.	2.0	88
50	Patient-reported outcomes from a randomised phase III study of baricitinib in patients with rheumatoid arthritis and an inadequate response to biological agents (RA-BEACON). <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 694-700.	0.9	83
51	Fenebrutinib Versus Placebo or Adalimumab in Rheumatoid Arthritis: A Randomized, Double-blind, Phase II Trial. <i>Arthritis and Rheumatology</i> , 2020, 72, 1435-1446.	5.6	83
52	Peficitinib, a JAK Inhibitor, in Combination With Limited Conventional Synthetic Disease-modifying Antirheumatic Drugs in the Treatment of Moderate-to-severe Rheumatoid Arthritis. <i>Arthritis and Rheumatology</i> , 2017, 69, 932-942.	5.6	78
53	Phase II Study of ABT122, a Tumor Necrosis Factor and Interleukin-17A Targeted Dual Variable Domain Immunoglobulin, in Patients With Psoriatic Arthritis With an Inadequate Response to Methotrexate. <i>Arthritis and Rheumatology</i> , 2018, 70, 1778-1789.	5.6	77
54	Low immunogenicity of tocilizumab in patients with rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 1078-1085.	0.9	76

#	ARTICLE	IF	CITATIONS
55	Serum 14-3-3 β is a Novel Marker that Complements Current Serological Measurements to Enhance Detection of Patients with Rheumatoid Arthritis. <i>Journal of Rheumatology</i> , 2014, 41, 2104-2113.	2.0	72
56	Tabalumab, an anti-BAFF monoclonal antibody, in patients with active rheumatoid arthritis with an inadequate response to TNF inhibitors. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 1461-1468.	0.9	66
57	Dose reduction of baricitinib in patients with rheumatoid arthritis achieving sustained disease control: results of a prospective study. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 171-178.	0.9	66
58	Immunogenicity, Safety, and Efficacy of Abatacept Administered Subcutaneously With or Without Background Methotrexate in Patients With Rheumatoid Arthritis: Results From a Phase III, International, Multicenter, Parallel- € Arm, Open- € Label Study. <i>Arthritis Care and Research</i> , 2013, 65, 718-728.	3.4	65
59	Transaminase Levels and Hepatic Events During Tocilizumab Treatment: Pooled Analysis of Long- € Term Clinical Trial Safety Data in Rheumatoid Arthritis. <i>Arthritis and Rheumatology</i> , 2017, 69, 1751-1761.	5.6	65
60	Longterm Safety and Efficacy of Abatacept Through 5 Years of Treatment in Patients with Rheumatoid Arthritis and an Inadequate Response to Tumor Necrosis Factor Inhibitor Therapy. <i>Journal of Rheumatology</i> , 2012, 39, 1546-1554.	2.0	61
61	Infections in baricitinib clinical trials for patients with active rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 1290-1297.	0.9	61
62	Results from a Phase IIA Parallel Group Study of JNJ-40346527, an Oral CSF-1R Inhibitor, in Patients with Active Rheumatoid Arthritis despite Disease-modifying Antirheumatic Drug Therapy. <i>Journal of Rheumatology</i> , 2015, 42, 1752-1760.	2.0	60
63	Increased pretreatment serum IFN- γ /IL- β ratio predicts non-response to tumour necrosis factor β inhibition in rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 1757-1762.	0.9	59
64	Safety and efficacy of neurostimulation with a miniaturised vagus nerve stimulation device in patients with multidrug-refractory rheumatoid arthritis: a two-stage multicentre, randomised pilot study. <i>Lancet Rheumatology</i> , The, 2020, 2, e527-e538.	3.9	59
65	Safety and efficacy of etanercept beyond 10 years of therapy in North American patients with early and longstanding rheumatoid arthritis. <i>Arthritis Care and Research</i> , 2011, 63, 373-382.	3.4	58
66	A Phase III, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study of 2 Dosing Regimens of Fostamatinib in Patients with Rheumatoid Arthritis with an Inadequate Response to a Tumor Necrosis Factor- β Antagonist. <i>Journal of Rheumatology</i> , 2014, 41, 2120-2128.	2.0	57
67	Safety and Efficacy of Baricitinib Through 128 Weeks in an Open-label, Longterm Extension Study in Patients with Rheumatoid Arthritis. <i>Journal of Rheumatology</i> , 2018, 45, 14-21.	2.0	57
68	Tocilizumab as monotherapy or in combination with nonbiologic disease-modifying antirheumatic drugs: Twenty-four-week results of an open-label, clinical practice study. <i>Arthritis Care and Research</i> , 2013, 65, 362-371.	3.4	56
69	Sarilumab plus methotrexate improves patient-reported outcomes in patients with active rheumatoid arthritis and inadequate responses to methotrexate: results of a phase III trial. <i>Arthritis Research and Therapy</i> , 2016, 18, 198.	3.5	56
70	Clinical Efficacy and Safety of Baminercept, a Lymphotoxin β Receptor Fusion Protein, in Primary Sjögren's Syndrome. <i>Arthritis and Rheumatology</i> , 2018, 70, 1470-1480.	5.6	56
71	ABT-122, a Bispecific Dual Variable Domain Immunoglobulin Targeting Tumor Necrosis Factor and Interleukin-17A, in Patients With Rheumatoid Arthritis With an Inadequate Response to Methotrexate. <i>Arthritis and Rheumatology</i> , 2018, 70, 1710-1720.	5.6	55
72	Mass cytometry as a platform for the discovery of cellular biomarkers to guide effective rheumatic disease therapy. <i>Arthritis Research and Therapy</i> , 2015, 17, 127.	3.5	53

#	ARTICLE	IF	CITATIONS
73	Safety profile of baricitinib for the treatment of rheumatoid arthritis over a median of 3 years of treatment: an updated integrated safety analysis. <i>Lancet Rheumatology</i> , The, 2020, 2, e347-e357.	3.9	51
74	Long-term Safety of Subcutaneous Abatacept in Rheumatoid Arthritis: Integrated Analysis of Clinical Trial Data Representing More Than Four Years of Treatment. <i>Arthritis and Rheumatology</i> , 2014, 66, 1987-1997.	5.6	48
75	Evaluation of hepatitis B virus in clinical trials of baricitinib in rheumatoid arthritis. <i>RMD Open</i> , 2020, 6, e001095.	3.8	48
76	A phase 2 dose-ranging study of subcutaneous tabalumab for the treatment of patients with active rheumatoid arthritis and an inadequate response to methotrexate. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 1453-1460.	0.9	47
77	Response to baricitinib based on prior biologic use in patients with refractory rheumatoid arthritis. <i>Rheumatology</i> , 2018, 57, 900-908.	1.9	47
78	Efficacy of VX-509 (decernotinib) in combination with a disease-modifying antirheumatic drug in patients with rheumatoid arthritis: clinical and MRI findings. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 1979-1983.	0.9	45
79	Safety of ixekizumab in adult patients with plaque psoriasis, psoriatic arthritis and axial spondyloarthritis: data from 21 clinical trials. <i>Rheumatology</i> , 2020, 59, 3834-3844.	1.9	45
80	Development of the American College of Rheumatology's Rheumatoid Arthritis Electronic Clinical Quality Measures. <i>Arthritis Care and Research</i> , 2016, 68, 1579-1590.	3.4	43
81	Long-term safety of sarilumab in rheumatoid arthritis: an integrated analysis with up to 7 years' follow-up. <i>Rheumatology</i> , 2020, 59, 292-302.	1.9	43
82	Effect of tocilizumab on neutrophils in adult patients with rheumatoid arthritis: pooled analysis of data from phase 3 and 4 clinical trials. <i>Rheumatology</i> , 2017, 56, kew370.	1.9	42
83	Effects of Baricitinib on Lipid, Apolipoprotein, and Lipoprotein Particle Profiles in a Phase IIb Study of Patients With Active Rheumatoid Arthritis. <i>Arthritis and Rheumatology</i> , 2017, 69, 943-952.	5.6	42
84	Effect of filgotinib, a selective JAK 1 inhibitor, with and without methotrexate in patients with rheumatoid arthritis: patient-reported outcomes. <i>Arthritis Research and Therapy</i> , 2018, 20, 57.	3.5	42
85	Unique Sjögren's syndrome patient subsets defined by molecular features. <i>Rheumatology</i> , 2020, 59, 860-868.	1.9	41
86	Association of HLA-DRB1 alleles with clinical responses to the anti-interleukin-17A monoclonal antibody secukinumab in active rheumatoid arthritis. <i>Rheumatology</i> , 2016, 55, 49-55.	1.9	40
87	Integrated safety analysis of filgotinib in patients with moderately to severely active rheumatoid arthritis receiving treatment over a median of 1.6 years. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 184-192.	0.9	40
88	OSKIRA-4: a phase IIb randomised, placebo-controlled study of the efficacy and safety of fostamatinib monotherapy. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 2123-2129.	0.9	39
89	First Report of Idiopathic Granulomatous Mastitis Treated with Methotrexate Monotherapy. <i>Journal of Rheumatology</i> , 2009, 36, 1559-1559.	2.0	38
90	Effect of Golimumab on Patient-reported Outcomes in Rheumatoid Arthritis: Results from the GO-FORWARD Study. <i>Journal of Rheumatology</i> , 2012, 39, 1185-1191.	2.0	38

#	ARTICLE	IF	CITATIONS
91	Safety and Efficacy of Subcutaneous Golimumab in Patients with Active Rheumatoid Arthritis despite Methotrexate Therapy: Final 5-year Results of the GO-FORWARD Trial. <i>Journal of Rheumatology</i> , 2016, 43, 298-306.	2.0	37
92	Long-Term Experience with Etanercept in the Treatment of Rheumatoid Arthritis in Elderly and Younger Patients. <i>Drugs and Aging</i> , 2006, 23, 167-178.	2.7	36
93	Safety and efficacy of ixekizumab in patients with PsA and previous inadequate response to TNF inhibitors: week 52 results from SPIRIT-P2. <i>Rheumatology</i> , 2018, 57, 2001-2011.	1.9	34
94	FKB327, an adalimumab biosimilar, versus the reference product: results of a randomized, Phase III, double-blind study, and its open-label extension. <i>Arthritis Research and Therapy</i> , 2019, 21, 281.	3.5	34
95	Methotrexate in the Treatment of Idiopathic Granulomatous Mastitis. <i>Journal of Rheumatology</i> , 2020, 47, 924-927.	2.0	34
96	Subcutaneous Abatacept for the Treatment of Rheumatoid Arthritis: Longterm Data from the ACQUIRE Trial. <i>Journal of Rheumatology</i> , 2014, 41, 629-639.	2.0	33
97	Joint and soft-tissue injection. <i>Postgraduate Medicine</i> , 1998, 103, 125-134.	2.0	31
98	Two years of sarilumab in patients with rheumatoid arthritis and an inadequate response to MTX: safety, efficacy and radiographic outcomes. <i>Rheumatology</i> , 2018, 57, 1423-1431.	1.9	31
99	Biologic Therapies in Clinical Development for the Treatment of Rheumatoid Arthritis. <i>Journal of Clinical Rheumatology</i> , 2005, 11, S45-S54.	0.9	30
100	Dual inhibition of tumour necrosis factor and interleukin-17A with ABT-122: open-label long-term extension studies in rheumatoid arthritis or psoriatic arthritis. <i>Rheumatology</i> , 2018, 57, 1972-1981.	1.9	30
101	Association of High Serum Interleukin-6 Levels With Severe Progression of Rheumatoid Arthritis and Increased Treatment Response Differentiating Sarilumab From Adalimumab or Methotrexate in a Post Hoc Analysis. <i>Arthritis and Rheumatology</i> , 2020, 72, 1456-1466.	5.6	30
102	Olokizumab, a monoclonal antibody against interleukin 6, in combination with methotrexate in patients with rheumatoid arthritis inadequately controlled by methotrexate: efficacy and safety results of a randomised controlled phase III study. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 469-479.	0.9	30
103	Safety and Efficacy of Filgotinib: Up to 4-year Results From an Open-label Extension Study of Phase II Rheumatoid Arthritis Programs. <i>Journal of Rheumatology</i> , 2021, 48, 1230-1238.	2.0	29
104	Safety and Efficacy of Open-label Subcutaneous Ixekizumab Treatment for 48 Weeks in a Phase II Study in Biologic-naïve and TNF-IR Patients with Rheumatoid Arthritis. <i>Journal of Rheumatology</i> , 2016, 43, 289-297.	2.0	28
105	Longterm Safety and Efficacy of Subcutaneous Abatacept in Patients with Rheumatoid Arthritis: 5-year Results from a Phase IIIb Trial. <i>Journal of Rheumatology</i> , 2018, 45, 1085-1092.	2.0	28
106	Non-invasive vagus nerve stimulation for rheumatoid arthritis: a proof-of-concept study. <i>Lancet Rheumatology</i> , The, 2021, 3, e262-e269.	3.9	28
107	Long-term safety and efficacy of sarilumab plus methotrexate on disease activity, physical function and radiographic progression: 5 years of sarilumab plus methotrexate treatment. <i>RMD Open</i> , 2019, 5, e000887.	3.8	27
108	TNF-alpha inhibition for the treatment of cardiac sarcoidosis. <i>Seminars in Arthritis and Rheumatism</i> , 2020, 50, 546-552.	3.4	27

#	ARTICLE	IF	CITATIONS
109	Safety results of ixekizumab with 1822.2 patient-years of exposure: an integrated analysis of 3 clinical trials in adult patients with psoriatic arthritis. <i>Arthritis Research and Therapy</i> , 2020, 22, 14.	3.5	27
110	Treatment of rheumatoid arthritis with etanercept. <i>Rheumatic Disease Clinics of North America</i> , 2004, 30, 311-328.	1.9	25
111	Apremilast in Patients With Active Rheumatoid Arthritis: A Phase II, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study. <i>Arthritis and Rheumatology</i> , 2015, 67, 1703-1710.	5.6	25
112	Secukinumab in Active Rheumatoid Arthritis after Anti-TNF α Therapy: A Randomized, Double-Blind Placebo-Controlled Phase 3 Study. <i>Rheumatology and Therapy</i> , 2017, 4, 475-488.	2.3	25
113	Effects of the oral Janus kinase inhibitor tofacitinib on patient-reported outcomes in patients with active rheumatoid arthritis: results of two Phase 2 randomised controlled trials. <i>Clinical and Experimental Rheumatology</i> , 2016, 34, 430-42.	0.8	23
114	A randomized, controlled trial of interferon-beta-1a (Avonex(R)) in patients with rheumatoid arthritis: a pilot study [ISRCTN03626626]. <i>Arthritis Research</i> , 2004, 6, R73.	2.0	22
115	Efficacy and safety of sarilumab in combination with csDMARDs or as monotherapy in subpopulations of patients with moderately to severely active rheumatoid arthritis in three phase III randomized, controlled studies. <i>Arthritis Research and Therapy</i> , 2020, 22, 139.	3.5	21
116	Results of a proof of concept, double-blind, randomized trial of a second generation antisense oligonucleotide targeting high-sensitivity C-reactive protein (hs-CRP) in rheumatoid arthritis. <i>Arthritis Research and Therapy</i> , 2015, 17, 80.	3.5	20
117	Interleukin-6 receptor blockade or TNF α inhibition for reducing glycaemia in patients with RA and diabetes: post hoc analyses of three randomised, controlled trials. <i>Arthritis Research and Therapy</i> , 2020, 22, 206.	3.5	20
118	Tissue metabolite of type I collagen, C1M, and CRP predicts structural progression of rheumatoid arthritis. <i>BMC Rheumatology</i> , 2019, 3, 3.	1.6	18
119	Improvement in Psoriasis Signs and Symptoms Assessed by the Psoriasis Symptom Inventory with Brodalumab Treatment in Patients with Psoriatic Arthritis. <i>Journal of Rheumatology</i> , 2016, 43, 343-349.	2.0	17
120	Long-term safety, immunogenicity and efficacy comparing FKB327 with the adalimumab reference product in patients with active rheumatoid arthritis: data from randomised double-blind and open-label extension studies. <i>RMD Open</i> , 2020, 6, e000987.	3.8	17
121	Phase II, randomised, double-blind, multicentre study evaluating the safety and efficacy of filgotinib and lanraplenib in patients with lupus membranous nephropathy. <i>RMD Open</i> , 2020, 6, e001490.	3.8	17
122	Diminished cytokine-induced Jak/STAT signaling is associated with rheumatoid arthritis and disease activity. <i>PLoS ONE</i> , 2021, 16, e0244187.	2.5	16
123	Comparative clinical efficacy and safety of the proposed biosimilar ABP 710 with infliximab reference product in patients with rheumatoid arthritis. <i>Arthritis Research and Therapy</i> , 2020, 22, 60.	3.5	14
124	Switching from adalimumab to tofacitinib in the treatment of patients with rheumatoid arthritis. <i>Arthritis Research and Therapy</i> , 2016, 18, 145.	3.5	12
125	Two-Year Safety and Effectiveness of Peficitinib in Moderate-To-Severe Rheumatoid Arthritis: A Phase IIb, Open-Label Extension Study. <i>Rheumatology and Therapy</i> , 2019, 6, 503-520.	2.3	12
126	Safety and Efficacy of Poseltinib, Bruton's Tyrosine Kinase Inhibitor, in Patients With Rheumatoid Arthritis: A Randomized, Double-blind, Placebo-controlled, 2-part Phase II Study. <i>Journal of Rheumatology</i> , 2021, 48, 969-976.	2.0	12

#	ARTICLE	IF	CITATIONS
127	Response to baricitinib therapy in patients with rheumatoid arthritis with inadequate response to csDMARDs as a function of baseline characteristics. RMD Open, 2018, 4, e000581.	3.8	11
128	Long-term safety and efficacy of sarilumab over 5 years in patients with rheumatoid arthritis refractory to TNF inhibitors. Rheumatology, 2021, 60, 4991-5001.	1.9	11
129	Long-term followup of patients treated with total lymphoid irradiation for lupus nephritis. Arthritis and Rheumatism, 2002, 46, 1014-1018.	6.7	10
130	Safety and efficacy of switching from adalimumab to sarilumab in patients with rheumatoid arthritis in the ongoing MONARCH open-label extension. RMD Open, 2019, 5, e001017.	3.8	9
131	A1.72â€¦Baricitinib, an oral janus kinase inhibitor, in the treatment of rheumatoid arthritis: safety and efficacy in an open-label, long-term extension study¹. Annals of the Rheumatic Diseases, 2014, 73, A31.2-A31.	0.9	8
132	Efficacy and Safety of Tabalumab, an Antiâ€œB-Cellâ€œActivating Factor Monoclonal Antibody, in a Heterogeneous Rheumatoid Arthritis Population. Journal of Clinical Rheumatology, 2015, 21, 231-238.	0.9	8
133	Immunogenicity of an adalimumab biosimilar, FKB327, and its reference product in patients with rheumatoid arthritis. International Journal of Rheumatic Diseases, 2020, 23, 1514-1525.	1.9	8
134	MRI and Dose Selection in a Phase II Trial of Baricitinib with Conventional Synthetic Disease-modifying Antirheumatic Drugs in Rheumatoid Arthritis. Journal of Rheumatology, 2019, 46, 887-895.	2.0	7
135	Treatment of Rheumatoid Arthritis. , 2009, , 1119-1143.		7
136	Management of co-morbidities and general medical conditions in patients with rheumatoid arthritis. Current Rheumatology Reports, 2005, 7, 407-415.	4.7	6
137	The road to rheumatoid arthritis prevention: challenges and opportunities. Clinical Rheumatology, 2020, 39, 1379-1381.	2.2	6
138	THU0078â€¦SAFETY PROFILE OF BARICITINIB FOR THE TREATMENT OF RHEUMATOID ARTHRITIS UP TO 7 YEARS: AN UPDATED INTEGRATED SAFETY ANALYSIS. , 2019, , .		5
139	Long-term safety and efficacy of olokizumab in patients with rheumatoid arthritis and inadequate response to tumor necrosis factor inhibitor therapy in phase II studies. , 2021, 8, 120-129.		5
140	Treatment of rheumatoid arthritis with total lymphoid irradiation: Long-term survival. Arthritis and Rheumatism, 2001, 44, 1525-1528.	6.7	4
141	The Incidence, Prevalence, and Associated Costs of Anemia, Malignancy, Venous Thromboembolism, Major Adverse Cardiovascular Events, and Infections in Rheumatoid Arthritis Patients by Treatment History in the United States. ACR Open Rheumatology, 2022, 4, 473-482.	2.1	4
142	Pooled analysis of TNF inhibitor biosimilar studies comparing radiographic progression by disease activity states in rheumatoid arthritis. RMD Open, 2020, 6, e001096.	3.8	3
143	A randomized, blinded, parallel group, placebo controlled pilot study evaluating the effect of PVAC treatment in patients with diffuse systemic sclerosis. Journal of Rheumatology, 2005, 32, 2345-50.	2.0	3
144	FRIO154â€¦SAFETY AND EFFICACY OF FILGOTINIB IN PATIENTS AGED 65 YEARS AND OLDER: RESULTS FROM A PHASE 3 STUDY IN PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS AND PRIOR INADEQUATE RESPONSE OR INTOLERANCE TO BIOLOGICAL DMARDS (BDMARD-IR). , 2019, , .		2

#	ARTICLE	IF	CITATIONS
145	SAT0121â€¦EFFECT OF SARILUMAB ON GLYCOSYLATED HEMOGLOBIN IN PATIENTS WITH RHEUMATOID ARTHRITIS AND DIABETES. , 2019, , .		2
146	LB0009â€¦ FIRST-IN-HUMAN STUDY OF NOVEL IMPLANTED VAGUS NERVE STIMULATION DEVICE TO TREAT RHEUMATOID ARTHRITIS. , 2019, , .		2
147	Radiographic progression based on baseline characteristics from TNF inhibitor biosimilar studies in patients with rheumatoid arthritis. Arthritis Research and Therapy, 2020, 22, 188.	3.5	2
148	Integrated safety analysis of filgotinib treatment for rheumatoid arthritis in patients from Japan over a median of 1.5â€‰years. Modern Rheumatology, 2023, 33, 64-72.	1.8	2
149	219â€‰Safety summary results of baricitinib focusing on serious infections events and preselected comorbidities. Rheumatology, 2018, 57, .	1.9	1
150	FRI0075â€¦SYSTEMATIC ANALYSIS OF INJECTION-SITE PAIN CAUSED BY SUBCUTANEOUS ADMINISTRATION OF THE ADALIMUMAB BIOSIMILAR FKB327 VERSUS ADMINISTRATION OF THE ADALIMUMAB REFERENCE PRODUCT VIA DIFFERENT DELIVERY METHODS. , 2019, , .		1
151	OP0029â€¦SWITCHING BETWEEN THE JAK1-SELECTIVE INHIBITOR-UPADACITINIB AND ADALIMUMAB FOLLOWING INITIAL NON-RESPONSE: CLINICAL AND FUNCTIONAL OUTCOMES AMONG RHEUMATOID ARTHRITIS PATIENTS. , 2019, , .		1
152	P235â€‰Glucocorticoid dose is progressively reduced in Patients with rheumatoid arthritis (RA) receiving sarilumab: results from the open label EXTEND study. Rheumatology, 2020, 59, .	1.9	1
153	Edward D. Harris, Jr., MD, 1937-2010. Arthritis and Rheumatism, 2010, 62, 2623-2624.	6.7	0
154	Dr. Genovese comments. Journal of Rheumatology, 2015, 42, 1994-1994.	2.0	0
155	077â€‰Immunogenicity of Subcutaneous and Intravenous Tocilizumab as Monotherapy or in Combination with Disease-Modifying Anti-Rheumatic Drugs in Rheumatoid Arthritis. Rheumatology, 0, , .	1.9	0
156	OO3.â€‰CLINICAL AND RADIOGRAPHIC OUTCOMES AFTER 3 YEARS OF SARILUMAB IN PATIENTS WITH RHEUMATOID ARTHRITIS. Rheumatology, 2017, 56, .	1.9	0
157	214â€‰Efficacy and safety of switching from adalimumab to sarilumab in an open-label extension of a phase III monotherapy trial in patients with active rheumatoid arthritis. Rheumatology, 2018, 57, .	1.9	0
158	233â€‰Durability, maintenance and effects of dose reduction following prolonged treatment with baricitinib. Rheumatology, 2018, 57, .	1.9	0
159	217â€‰Improvements in remission and low disease activity are achieved with ongoing sarilumab treatment, in patients with rheumatoid arthritis in two phase III studies. Rheumatology, 2018, 57, .	1.9	0
160	086â€‰Safety and efficacy of filgotinib in a phase 3 trial of patients with active rheumatoid arthritis and inadequate response or intolerance to biologic disease modifying anti-rheumatic drugs. Rheumatology, 2019, 58, .	1.9	0
161	THU0173â€¦FILGOTINIB IN PATIENTS WITH RHEUMATOID ARTHRITIS AND PRIOR INADEQUATE RESPONSE OR INTOLERANCE TO BIOLOGICAL DMARDS (BDMARD-IR) BY RACE & GEOGRAPHIC REGION. , 2019, , .		0
162	SAT0132â€¦LONG-TERM SAFETY, IMMUNOGENICITY AND EFFICACY IN RANDOMIZED, DOUBLE-BLIND, AND OPEN-LABEL EXTENSION STUDIES COMPARING FKB327, AN ADALIMUMAB BIOSIMILAR, WITH THE ADALIMUMAB REFERENCE PRODUCT IN PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS. , 2019, , .		0

#	ARTICLE	IF	CITATIONS
163	FRI0092â€¦SAFETY AND EFFICACY OF FILGOTINIB IN ACTIVE RHEUMATOID ARTHRITIS BY PRIOR BIOLOGICAL DMARD EXPOSURE IN PATIENTS WITH PRIOR INADEQUATE RESPONSE OR INTOLERANCE TO BIOLOGICAL DMARDS (BDMARD-IR). , 2019, , .		0
164	AB0448â€¦SAFETY AND EFFICACY OF FILGOTINIB IN JAPANESE PATIENTS ENROLLED IN A GLOBAL PHASE 3 TRIAL OF PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS AND INADEQUATE RESPONSE OR INTOLERANCE TO BIOLOGIC DMARDS. , 2019, , .		0
165	P225â€¦Inhibition of structural joint damage with upadacitinib as monotherapy or in combination with MTX in patients with RA: one-year outcomes from the select Phase 3 programme. Rheumatology, 2020, 59, .	1.9	0
166	O09â€¦Pooled safety analyses from Phase 3 studies of filgotinib in patients with RA. Rheumatology, 2020, 59, .	1.9	0
167	P171â€¦Efficacy and safety of upadacitinib in patients with active PsA and inadequate response to biologic DMARDs (SELECT-PsA-2): a double-blind, randomised controlled Phase III trial. Rheumatology, 2021, 60, .	1.9	0